Sanofi SA
SNW
Company Profile
Business description
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
Contact
46, Avenue de la Great Army
Paris75017
FRAT: +33 153774000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
74,846
Stocks News & Analysis
stocks
Our view after CBA shares plunge
Steady profit, but rising risks and rich valuation give pause.
stocks
Ahead of earnings, is Nvidia a buy, a sell, or fairly valued?
Amid robust demand for semis, watch for any impact of in-house built chips and whether the supply chain is on track.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,862.50 | 3.90 | -0.04% |
| CAC 40 | 8,007.97 | 28.05 | 0.35% |
| DAX 40 | 24,136.81 | 181.88 | 0.76% |
| Dow JONES (US) | 49,693.20 | 67.36 | -0.14% |
| FTSE 100 | 10,325.35 | 60.03 | 0.58% |
| HKSE | 26,552.89 | 164.45 | 0.62% |
| NASDAQ | 26,402.34 | 314.14 | 1.20% |
| Nikkei 225 | 63,448.87 | 176.76 | 0.28% |
| NZX 50 Index | 13,020.65 | 42.41 | -0.32% |
| S&P 500 | 7,444.25 | 43.29 | 0.58% |
| S&P/ASX 200 | 8,617.70 | 3.00 | 0.03% |
| SSE Composite Index | 4,208.14 | 34.43 | -0.81% |